Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SurVaxM in Pediatric Patients With Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed DIPG
NCT04978727Phase 1Active, not recruiting
- Sponsor
- Children's Oncology Group
- Start
- Jul 2022
- Primary completion
- Dec 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of SurVaxM in medulloblastoma, glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) and 5 more (3 arms), sponsored by Children's Oncology Group. Primary endpoints: Regimen-Limiting Toxicity at 8 weeks and Pseudoprogression Related Regimen-Limiting Toxicity at 14 weeks. Started Jul 2022; status: active, not recruiting.
02
Drugs
SurVaxM
03
Conditions
medulloblastomaglioblastoma multiforme (GBM)anaplastic astrocytoma (AA)high-grade astrocytomaanaplastic oligodendroglioma (AO)
Beyond the preview
Go deeper on NCT04978727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978727.